Differences in insulin treatment satisfaction following randomized addition of biphasic, prandial or basal insulin to oral therapy in type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 13, Issue 12, 2011, Pages 1136-1141

  Farmer, A J ^a,b   Oke, J ^a,b   Stevens, R ^a,b   Holman, R R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Clinical diabetes; Hypoglycaemia; Insulin therapy; Psychological aspects

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; INSULIN ASPART; INSULIN DETEMIR; METFORMIN; SULFONYLUREA;

ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DISEASE DURATION; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIAL;

EID: 80055058298     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01475.x     Document Type: Article

References (14)

1. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393.
2. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
3. Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 2005; 28: 2543-2545.
4. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002; 3: S18-S24.
5. Woolpert HA, Anderson BJ. Management of diabetes: are doctors framing the benefits from the wrong perspective? BMJ 2001; 323: 994-996.
6. Holman RR, Thorne KI, Farmer AJ et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357: 1716-1730.
7. Group E. EuroQol: a new facility for the measurement of health related quality of life. Health Pol 2001; 16: 199-208.
8. Anderson RT, Skovlund SE, Marrero D et al. Development and validation of the insulin treatment satisfaction questionnaire. Clin Ther 2004; 26: 565-578.
9. Davis TM, Clifford RM, Davis WA. Fremantle Diabetes Study: effect of insulin therapy on quality of life in type 2 diabetes mellitus: the Fremantle diabetes study. Diabetes Res Clin Pract 2001; 52: 63-71.
10. UK Prospective Diabetes Study (UKPDS) Group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 1999; 22: 1125-1136.
11. van der Does FE, de Neeling JND, Snoek FJ et al. Randomized study of two different target levels of glycaemic control within the acceptable range in type 2 diabetes. Diabetes Care 1998; 21: 2085-2093.
12. Christensen B. Psychological reactions to information about risk of ischaemic heart disease in general practice. Scand J Prim Health Care 1995; 13: 164-167.
13. Brod M, Cobden D, Lammert M, Bushnell D, Raskin P. Examining correlates of treatment satisfaction for injectable insulin in type 2 diabetes: lessons learned from a clinical trial comparing biphasic and basal analogues. Health Qual Life Outcomes 2007; 5: 8.
14. Rubin RR, Peyrot M, Kruger DF, Travis LB. Barriers to insulin injection therapy: patient and health care provider perspectives. Diabetes Educ 2009; 35: 1014-1022.